Rediscover NASH Club: 3 episodes through the management of MASLD/MASH

*NAFLD-NASH is now called MASLD-MASH due to the 2023 new nomenclature.

MASH disease is a growing public health crisis. 76%* of individuals with type 2 diabetes (T2D) and 90%** of obese adults have nonalcoholic fatty liver disease (MASLD). Given MASLD close association with T2D and obesity , the prevalence of both MASLD and MASH is likely to continue to increase with and estimation of 30%*** of MASH patients developing liver fibrosis that can progress to Cirrhosis and to Hepatocellular Carcinoma.

You will learn from 12 EU top experts of a wide range of medical specialties: Hepatologists, Gastroenterologists, Diabetologists, Endocrinologists, and General practitioners.

You can register for free once and attend the full series. 

Echosens gives institutional support to the event.